About LUZHU BIOTECH-B Company

The company is a biotechnology company dedicated to developing innovative human vaccines and therapeutic biologics to prevent and control infectious diseases and treat cancer and autoimmune diseases. Since its establishment in 2001, the Group has focused on the field of human medicine, and has established a technical platform based on its understanding of immunology and protein engineering, so that the Group can develop recombinant vaccines and antibody products with improved efficiency, high purity and stability. As of December 31, 2023, the Group's product pipeline includes three clinical-stage products under development, one of which is the core product LZ901, and four pre-clinical products under development. As of December 31, 2023, the Group has 3 R&D patents related to core products and 6 pending approval applications. All registered patents and patent applications for core products relate to the same set of patent claims filed in nine different jurisdictions to protect the core product. This is because in addition to China and the US, other jurisdictions are also future target markets or potential markets for LZ901. In April 2024, the Group was granted invention patents for its core products in the US and Australia. The Company's H shares were listed on the Stock Exchange on May 8, 2023. The total net proceeds of the Company's global offering of H shares (“Global Offering”) (net of underwriting commissions and other expenses payable by the Company in connection with the global offering) is approximately HK$241.6 million.